期刊文献+

非钙性磷酸盐结合剂的应用进展 被引量:1

Clinical use of non-calcium phosphate binder:an advance
原文传递
导出
摘要 控制血清磷水平对终末期肾病(ESRD)患者非常重要,目前临床普遍使用磷酸盐结合剂来治疗高磷血症。理想的治疗目标在于降低血清磷水平的同时不打破体内钙的平衡,减少药物引起的潜在毒性物质的积累。常用的控制血磷水平的药物有氢氧化铝和钙结合剂等,前者能有效地降低血磷,但金属铝易在体内积累并产生毒性;后者会促进高钙血症和钙超载的发生,加速心血管钙化。因此非铝、非钙类结合剂是当前研究热点,此类药物如司维拉姆、碳酸镧能有效降低血清磷,但由于价格因素未能广泛应用;考来替兰、烟酸和镁盐等新一代的非钙类磷酸盐结合剂,与原有非钙类磷酸盐结合剂相比其价格更便宜,但远期效果及安全性还有待观察。本文详细介绍了各种非钙类磷酸盐结合剂在ESRD中的应用进展,以期对临床用药有所帮助。 Controlling serum phosphorus levels is critical in patients with renal failure. Currently phosphate-binding agents are widely used to reduce phosphate absorption in patients with endstage renal disease. If possible,serum phosphorus level should be reduced without disturbing calcium homeostasis or increasing accumulation of potentially toxic elements. Aluminum hydroxide and traditional calcium -based phosphate binders are commonly used to control serum phosphorus level. Aluminum hydroxide can effectively lower serum phosphorus level,but aluminum can accumulates in the body and results in toxic effect. Traditional calcium-based phosphate binders tend to promote hypercalcemia and calcium overloading,and accelerate cardiovascular calcification. Therefore aluminum -free and calcium-free phosphate-binding agents have become the focus of study; however,agents like sevelamer hydrochloride and lanthanum carbonate are not widely used due to high price,although they are effective in controlling serum phosphorus level. New generation of phosphate binders,such as colestilan,nicotinic acid and magnesium salt,are cheaper than their previous counterparts,but their long -term effect still needs to be observed. This article summarizes the progress of non-calcium phosphate binders in treatment of end-stage renal diseases,hoping to help clinical drug usage.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2010年第1期94-96,共3页 Academic Journal of Second Military Medical University
关键词 非钙性磷酸盐结合剂 终末期肾病 高磷血症 non-calcium phosphate binder end-stage renal disease phosphotaemia
  • 相关文献

参考文献22

  • 1Foley R N,Collins A J,Herzog C A,Ishani A,Kalra P A. Serum phosphorus levels associate with coronary atherosclerosis in young adults[J]. J Am Soc Nephrol, 2009,20 : 397-404.
  • 2Isakova T, Gutierrez O M, Chang Y, Shah A, Tamez H, Smith K,et al. Phosphorus binders and survival on hemodialysis[J]. J Am Soc Nephrol, 2009,20 : 388-396.
  • 3Hutchison A J. Improving phosphate-binder therapy as a way forward[J]. Nephrol Dial Transplant, 2004,19 (Suppl 1) : Ⅰ19-Ⅰ24.
  • 4Koiwa F,Onoda N, Kato H, Tokumoto A, Okada T, Fukagawa M,et al. Prospective randomized muhicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphataemia in hemodialysis patients in Japan[J]. Ther Apheresis Dial, 2005,9: 340-346.
  • 5Nikolov I G, Joki N, Maizel J, Lacour B, Drueke T B, Massy Z A. Pleiotropic effects of the non-calcium phosphate binder sevelamer[J]. Kidney Int Suppl,2006(105) :S16-S23.
  • 6Shantouf R, Budoff M J, Ahmadi N, Tiano J, Flores F, Kalantar- Zadeh K. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients[J]. Am J Nephrol, 2008,28 : 275-279.
  • 7Mitsopoulos E, Griveas I, Zanos S, Anagnostopoulos K, Giannakou A,Pavlitou A, et al. Increase in serum magnesium level in haemodialysis patients receiving sevelamer hydrochloride[J]. Int Urol Nephrol, 2005,37 : 321-328.
  • 8Sprague S M,Abboud H,Qiu P,Dauphin M,Zhang P,Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4:a randomized trial[J]. Clin J Am Soc Nephrol, 2009,4 : 178-185.
  • 9Autissier V, Damment S J, Henderson R A. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydroehtoride[J]. J Pharm Sci, 2007,96 : 2818-2827.
  • 10Neehama M, Ben Dov I Z, Silver J, Naveh-Many T. Regulatiorr of PTH mRNA stability by the calcimimetie R568 and the phosphorus binder lanthanum carbonate in CKD[J]. Am J Physiol Renal Physiol, 2009,296 : F795-F800.

二级参考文献13

  • 1沈磊.抗高磷酸血症新药碳酸镧[J].药学进展,2005,29(6):286-287. 被引量:4
  • 2郑平东,朱燕俐.用腺嘌呤制作慢性肾功能衰竭动物模型[J].中华肾脏病杂志,1989,5(6):342-344. 被引量:115
  • 3杜卉莲,傅晓晴.慢性肾衰动物的模型制备及临床应用[J].中医研究,2005,18(12):53-57. 被引量:27
  • 4黄新忠,范亚平,蒋季杰.两种非铝非钙新型磷结合剂的药理与临床[J].国际泌尿系统杂志,2006,26(2):276-279. 被引量:4
  • 5BlocL Port FK.Calcium phosphatemotabolism and cardiovascular disease in patients with chronic kidney disease[J].SeminDial,2003,16:140-147.
  • 6WangAY,WangM,Woo J,et al.Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysiS patients:a prospective study[J].J Am Soc Nephrol,2003,14(1):159-168.
  • 7Raggi P,Boulay A,Chasen-Taber S.Cardiac calcification in adult hemodialysis patients:A line between end-stage renal disease and cardiovascular disease[J].J Aln Coll Cardiol,2002,39:695-701.
  • 8Almaden Y,Hernandez,A.High phosphate level directly stimulates parathyroid tissue in vitro[J].J Am Soc Nephrol,1998,9:1845-1852.
  • 9Francesco Locatelli,Jorge B.Management of disturbance of calcium and phosphate metabolism in chronic renal insufficiency,with emphasis on the control of hyperphosphataemia[J].Nephrol Dial Transplant,2002,17:723-731.
  • 10Yokozawz T. Anmial model of adenine-induced chronic renal failure in rate[J]. Nephron , 1986;44:230 - 236.

共引文献5

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部